http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Michael Prayogo,Damayanti Tinduh,Dewi Poerwandari,Rwahita Satyawati Dharmanta,Sri Mardjiati Mei Wulan,Yukio Mikami,Soenarnatalina Melaniani 대한노인병학회 2022 Annals of geriatric medicine and research Vol.26 No.4
Background: Aging causes locomotive syndrome (LS), which is characterized by difficulty in walking. The present study determined the effects of locomotion training and regular aerobic exercise programs on the aerobic capacity of older nursing home residents with LS stage 1. Methods: This randomized controlled trial included 24 participants aged 60-80 years with LS stage 1 residing in a single nursing home in Surabaya, Indonesia. The participants were randomly assigned to either the locomotion training group (LTG) or the control group (CG). Both the groups performed 30 minutes of a daily group-based aerobic exercise program for 8 weeks. The LTG performed additional locomotion training three times weekly, with three sets per session, gradually increasing to five sets per session according to the participant’s tolerance. Two-minute walking test (2MWT) values before and after the 8-week intervention were determined in both the groups and converted to maximum oxygen consumption (VO2max) values. Results: After 8 weeks of intervention, a significant increase in VO2max was observed in both the groups (both p<0.05). The LTG showed a more significant improvement in VO2max (p<0.05) compared to the CG. Conclusion: The study results demonstrated the positive effect of 8 weeks of locomotion training and regular aerobic exercise programs in improving the aerobic capacity of older adult nursing home residents with LS stage 1.
Sutandyo, Noorwati,Firna, Evi,Agustina, Julyanti,Prayogo, Nugroho,Widjaja, Leovinna Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.15
Background: Even though rarely found in Indonesia, the incidence of multiple myeloma (MM) is increasing every year. Bone involvement of MM is the most often a clinical disorder which leads to worsening clinical conditions and low quality of life of patients. Purpose: To determine the clinicopathology profile of bone involvement of MM patients in Indonesia. Materials and Methods: The cross-sectional study of MM conducted at Dharmais National Cancer Hospital (DNCH) by collecting data from medical records of MM patients who came to DNCH in period 2008-2012. Results: There were 39 MM patients all with age above 60 years. There were 56.4% male and 43.6% female patients. Most were diagnosed at stage III (32.4%), and 41% had obesity. The comorbid conditions were anemia (82.9%), hypoalbuminemia (60%), increased creatinine level (38.5%), increased ${\beta}2$ microglobulin level (94.1%), increased LDH level (23.1%) and plasmocytes above 30% (65%), but only 4.2% patients presented with hypercalcemia. Meanwhile, bone involvement occurred in 76.9% of MM patients with 4 lesions on average and a maximum of 16 lesions. The locations of bone lesions were spine (70%), skull (70%), pelvis (33.3%), humerus (30%), and femur (30%). Conclusions: The incidence of MM in Indonesia is increasing annually with bone involvement in more than three-fourths, but interestingly without hypercalcemia.
Soft-tissue Sarcomas in the Asia-Pacific Region: A Systematic Review
Ngan, Roger,Wang, Edward,Porter, David,Desai, Jayesh,Prayogo, Nugroho,Devi, Beena,Quek, Richard Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.11
Background: Soft-tissue sarcomas require tailored and multidisciplinary treatment and management. However, little is known about how sarcomas are treated and managed throughout the Asia-Pacific region. Materials and Methods: MEDLINE was systematically searched using prespecified criteria. Publications (previous 10 years) that reported tumour characteristics, treatment patterns, survival outcomes, and/or safety outcomes of patients with soft-tissue sarcoma were selected. Exclusion criteria were studies of patients <18 years of age; ${\leq}10$ patients; countries other than Australia, Hong Kong, Indonesia, Korea, Malaysia, New Zealand, Philippines, Singapore, Taiwan, or Thailand; >20% benign tumours; sarcomas located in bones or joints; gastrointestinal stromal tumour; Kaposi's sarcoma; or not reporting relevant outcomes. Results: Of the 1,822 publications retrieved, 35 (32 studies) were included. Nearly all patients (98%, 1,992/2,024; 31 studies) were treated with surgery, and more studies used adjuvant radiotherapy than chemotherapy (24 vs 17 studies). Survival outcomes and recurrence rates varied among the studies because of the different histotypes, sites, and disease stages assessed. Only 5 studies reported safety findings. Conclusions: These findings highlight the lack of specific data available about soft-tissue sarcomas in the Asia-Pacific region. Better efforts to understand how the sarcoma is managed and treated will help improve patient outcomes in the region.
( Merlyna Savitri ),( Rano Ismail ),( Ugroseno Yudho Bintoro ),( Rachmad Romdoni ),( Ami Ashariati Prayogo ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: To study the incidence of doxorubicin cardiotoxicity of in NHL patients who received CHOP (cyclophosphamide, doxorubicin, oncovin, prednisone) regimen in Dr.Soetomo Hospital, using echocardiography (EF, ejection fraction). Methods: Fifteen NHL patients treated with CHOP were studied longitudinally. Echocardiography was done in patients at baseline, and after cumulative dose of doxorubicin = 200 and = 300 mg/m². Cardiotoxicity was defined as a decrease of LVEF = 10% from baseline or absolute LVEF < 50%. Results: There was a decrease of mean LVEF after cumulative dose of doxorubicin = 200 mg/m² (2.87% from baseline, p>0,05) but without cardiotoxicity effect. There was a significant decrease of mean LVEF of 6,36% from baseline (p<0,05) after cumulative dose of doxorubicin = 300 mg/m² with cardiotoxicity effect observed in 2 patients (13,3%). The decrement of LVEF of these 2 patients were 10.45% and 26.09%. Conclusions: Cardiotoxicity effects were observed significantly in NHL patients receiving CHOP regimen. after cumulative doses of doxorubicin = 300 mg/m² (or after the 6th cycle)